Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Cabaletta Bio, Inc. CABA |
Baker Bros. Advisors LP | 1,344,000 5.200% |
1,344,000 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | CYTEIR THERAPEUTICS INC CYTT |
Baker Bros. Advisors LP | 2,492,118 7.000% |
2,492,118 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Immatics N.V. IMTX |
Baker Bros. Advisors LP | 5,187,081 6.800% |
763,350 (+17.26%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Replimune Group, Inc. REPL |
Baker Bros. Advisors LP | 5,768,227 9.990% |
5,768,227 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
Baker Bros. Advisors LP | 6,354,608 11.300% |
291,906 (+4.81%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Baker Bros. Advisors LP | 2,168,000 5.100% |
2,168,000 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Baker Bros. Advisors LP | 2,879,825 5.200% |
2,879,825 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Nurix Therapeutics, Inc. NRIX |
Baker Bros. Advisors LP | 4,801,954 9.990% |
2,347,872 (+95.67%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Madrigal Pharmaceuticals, Inc. MDGL |
Baker Bros. Advisors LP | 1,545,113 9.000% |
45,900 (+3.06%) |
Filing History |
| 2023-02-10 4:29 pm Sale |
2023-01-31 | 13G | Otonomy, Inc. OTIC |
Baker Bros. Advisors LP | 0 0.000% |
-3,448,263 (Position Closed) |
Filing History |
| 2023-01-17 4:32 pm Purchase |
2023-01-12 | 13D | ACADIA Pharmaceuticals Inc. ACAD |
Baker Bros. Advisors LP | 42,306,789 26.100% |
1,138,932 (+2.77%) |
Filing History |
| 2022-12-12 4:49 pm Sale |
2022-11-30 | 13G | Amarin Corporation plc AMRN |
Baker Bros. Advisors LP | 0 0.000% |
-1,064,659 (Position Closed) |
Filing History |
| 2022-11-10 4:35 pm Sale |
2022-10-31 | 13G | Otonomy, Inc. OTIC |
Baker Bros. Advisors LP | 3,448,263 6.100% |
-4,396,429 (-56.04%) |
Filing History |
| 2022-10-07 4:20 pm Purchase |
2022-09-30 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
Baker Bros. Advisors LP | 6,062,702 10.900% |
2,199,463 (+56.93%) |
Filing History |
| 2022-07-20 5:12 pm Purchase |
2022-07-15 | 13D | Immunocore Holdings plc IMCR |
Baker Bros. Advisors LP | 4,685,690 9.930% |
1,333,333 (+39.77%) |
Filing History |
| 2022-06-13 5:27 pm Purchase |
2022-06-07 | 13D | Talis Biomedical Corporation TLIS |
Baker Bros. Advisors LP | 2,500,336 66.400% |
4,389 (+0.18%) |
Filing History |
| 2022-06-13 5:23 pm Purchase |
2022-06-08 | 13D | DBV Technologies S.A. DBVT |
Baker Bros. Advisors LP | 1,174,483 24.980% |
616,250 (+110.39%) |
Filing History |
| 2022-06-06 5:10 pm Purchase |
2022-06-03 | 13D | Kodiak Sciences Inc. KOD |
Baker Bros. Advisors LP | 17,353,846 33.400% |
922,755 (+5.62%) |
Filing History |
| 2022-05-18 5:23 pm Purchase |
2022-05-16 | 13D | Kodiak Sciences Inc. KOD |
Baker Bros. Advisors LP | 16,431,091 31.600% |
865,023 (+5.56%) |
Filing History |
| 2022-05-12 4:45 pm Purchase |
2022-05-10 | 13D | TScan Therapeutics, Inc. TCRX |
Baker Bros. Advisors LP | 2,784,792 14.700% |
1,359,792 (+95.42%) |
Filing History |